You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Ellipta inhaler products

The Ellipta inhaler product range is a portfolio of evidence-based medicines for COPD and Asthma, all delivered in the same easy-to-use device. 1

To find out how the Ellipta portfolio can help your patients, explore the products below:

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) pack shot

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol)

COPD

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA). 2

Find out more

Anoro Ellipta (umeclidinium/vilanterol inhalation powder) pack shot

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

COPD

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 3

Find out more

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder) pack shot

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Asthma

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists; patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. 4

Incruse Ellipta (umeclidinium bromide inhalation powder) pack shot

Incruse Ellipta (umeclidinium bromide inhalation powder)

COPD

Incruse Ellipta is indicated for the maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 5

Response to queries about Ellipta inhalers

We have received a number of queries regarding our Ellipta inhalers and their association to Vectura.

  • GSK developed, manufactures and owns all IP rights for Ellipta inhalers and we are not in a partnership with Vectura.
  • The Ellipta inhaler is the product of over 10 years of planning, development and design by GSK.
  • The Ellipta inhaler range is manufactured and tested by GSK at Ware, England and Zebulon, US.
  • As per historical business agreement which expires in the next three years, GSK does pay royalties for patent licences to a company acquired by Vectura (SkyePharma). The license is to allow access to SkyePharma's formulation technology relating to the use of magnesium stearate as an excipient in inhalers to give GSK confidence that it can bring its medicines to patients.
  • GSK offers a variety of treatment options for asthma and COPD and will continue to invest in research and improving patient outcomes. 

Ellipta Inhaler Device

How to use Ellipta inhaler video

Watch our short video for patients on how to use the Ellipta inhaler.

Note: The Ellipta demonstration inhaler should be replaced once the dose counter reaches zero.

IMPORTANT: The Ellipta demonstration device is intended for demonstrating only and not for patient use. Patients should not put the demonstration inhaler in their mouth.

How to use the Ellipta inhaler

The package should only be opened when the patient is ready to begin using the inhaler. Once it is, tear open the foil, it should be used within 6 weeks. The "Discard by" date should be written on the inhaler label in the space provided. The “Discard by” date is 6 weeks from the date of opening the tray. After this date the inhaler should no longer be used. The tray can be discarded after first opening.

Stepwise approach for patients:

Opening the Ellipta inhaler

Open:

  • Slide the cover down until you hear a ‘click

  • While holding the inhaler away from your mouth, breathe out as far as is comfortable
Inhaling the Ellipta inhaler

Inhale:

  • Put the mouthpiece between your lips, and close your lips firmly around it

  • Take one long, steady, deep breath in and hold this breath for at least 3-4 seconds

 

Closing the Ellipta inhaler

Close:

  • Remove the inhaler from your mouth and breathe out slowly and gently

  • Slide the cover upwards as far as it will go to cover the mouthpiece

  • It is not necessary to clean the mouthpiece. If you choose to do so, always use a dry tissue

Always advise patients to read the instructions in the product's patient information leaflet prior to use.

IMPORTANT: The Ellipta Inhalation Trainer is designed to show the HCP that a patient is using the correct inhalation technique for the Ellipta device. If used correctly the trainer will make a whistling sound.

Getting Started

Before your patient starts using their active inhaler, you should consider the following:

The Ellipta demonstration inhaler is packaged in a tray containing a dessicant gel sachet, which should be thrown away with the other packaging.

When it is taken out of the tray, the inhaler will be in the ‘closed’ position (the cover will be shut). It is ready to use straight from the packaging, so there is no need to prepare it for use in any special way. 

Ellipta inhaler

IMPORTANT: If your patient opens and closes the cover of their inhaler without inhaling the medicine, the dose will be lost. Your patient should be ready to take the medicine before opening the cover.

Please note

  • It may not be possible to taste or feel the medicine, even when using the inhaler correctly
  • The patient should be careful not to shake the inhaler, block the air vents with their fingers, or breathe out into the inhaler
  • The dose counter will count down by one unit at a time. If the dose counter does not count down when you hear the ‘click’, the inhaler will not deliver the required dose. If this happens, your patient should take the inhaler back to the pharmacy.
  • For Trelegy Ellipta and Relvar Ellipta, it is recommended to rinse your mouth with water after you have used the inhaler, do not swallow.

References

  1. Van der Palen, J., et al., NPJ Primary Care Respiratory Medicine, 2016. 26: p. 16079.
  2. GlaxoSmithKline UK. Trelegy Ellipta 92/55/22 mcg inhalation powder Summary of Product Characteristics.
  3. GlaxoSmithKline UK. Anoro Ellipta 55/22 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.
  4. GlaxoSmithKline UK. Relvar Ellipta 92/22 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.
  5. GlaxoSmithKline UK. Incruse 55 mcg inhalation powder, pre-dispensed Summary of Product Characteristics.

Anoro, Incruse, Relvar, Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies